Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer

Authors

  • Claus K. Høgdall Department of Clinical Biochemistry, Statens Seruninsti-tut, Copenhagen, Denmark
  • Estrid V.S. Høgdall Laboratory of Molecular Biology, Statens Seruminstitut, Copenhagen, Denmark
  • Ulla Hørding Department of Obstetrics & Gyne-cology, Rigshospitalet, University of Copenhagen, Denmark
  • Kim Toftager-Larsen Department of Obstetrics & Gyne-cology, Rigshospitalet, University of Copenhagen, Denmark
  • Jørgen Arends Department of Clinical Biochemistry, Statens Seruninsti-tut, Copenhagen, Denmark
  • Bent Nørgaard-Pedersen Department of Clinical Biochemistry, Statens Seruninsti-tut, Copenhagen, Denmark
  • Inge Clemmensen Department of Clinical Microbiology of Rigshospitalet, University of Copenhagen, Denmark; DAK.O A/S, Giostrup, Denmark

DOI:

https://doi.org/10.3109/02841869609098481

Abstract

Tetranectin (TN), CA-125 and CASA were measured in serum prior to 63 second-look and 5 third-look operations for ovarian cancer. Patients with residual tumor had significantly lower levels of TN and higher levels of CASA and CA-125 compared with tumor-free patients. The predictive values PVPos = 100% and PVNeg = 50.9% were found for TN at 9.3 mg/1. For CASA, a predictive value PVPos = 100% was found at 10 U/ml with a corresponding PVNeg = 52.7%. At the cut-off 35 U/ml for CA-125, the PVPos was 100% and the PVNeg = 53.6%. By combining the markers, PVNeg increased to 61.7% with a PVPos on 100%. Significantly differences in survival were found by lifetable analysis between patients tested as positive and negative respectively for any of the markers. Using multivariate Cox analyses, it was found that every marker had an independent prognostic function for survival.

Downloads

Download data is not yet available.

Downloads

Published

1996-01-01

How to Cite

Høgdall, C. K., Høgdall, E. V., Hørding, U., Toftager-Larsen, K., Arends, J., Nørgaard-Pedersen, B., & Clemmensen, I. (1996). Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer. Acta Oncologica, 35(1), 63–69. https://doi.org/10.3109/02841869609098481

Issue

Vol. 35 No. 1 (1996): Acta Oncologica

Section

Articles